Child-appropriate drug formulations are a prerequisite of successful drug therapy in children. Efficacy and safety must be given for the active pharmaceutical ingredient, but safety also for the used excipients, components of primary packaging materials, and devices. We are presently experiencing exciting times for pediatric drug development, stimulated by previous governmental incentives in both the European Union and the United States. The most important advances in pediatric drug formulation development are reviewed and evaluated in this article. Scientific publications and recent industry strategies indicate a clear shift from liquid dosage forms to novel solid dosage forms. Solid formulations are usually composed from excipients generally regarded as safe, whereas many liquid formulations contain excipients such as preservatives, antioxidants, or taste-masking agents that raise concerns. Further, some recent clinical studies on swallowability, acceptability, and preference indicate superiority for small-sized tablets, so-called mini-tablets, over conventional liquids. In general, multiparticulate solid dosage forms could partly replace the liquids and provide more stable and cheaper alternatives to existing drug products or new developments. Dispersible solid drug dosage forms like orodispersible tablets, mini-tablets and films are even better opportunities for efficient and safe use in pediatrics. Novel measuring and administration devices may facilitate the handling and drug administration of these modern drug dosage forms. Combination products (drug-device combinations) can easily be linked with new e-health technologies in near future to further improve pediatric drug therapy.
Child-appropriate drug formulations are required for efficient and safe therapy of diseases in childhood. Children have different needs and requirements compared to adults. Due to the continuously varying characteristics of the juvenile organism during physiologic and cognitive maturation, the pediatric subpopulations are an inhomogeneous collective. Various authorized and often used medicines do not adequately reflect the needs of children.
In the United States and the European Union, several attempts have been made to improve the situation and to bridge the gaps in pediatric medicines. Ten years ago, in January 2007, the European Directive No. 1901/2006 on "medicinal products for paediatric use" came into force. 1 Basic pillars of the regulation were the introduction of a Pediatric Committee at the European Medicines Agency (EMA) and of a mandatory Pediatric Investigation Plan (PIP) to be submitted at the end of clinical phase I and to be negotiated with the Pediatric Committee in detail. The PIP comprises all foreseen requirements, actions, and goals during preclinical and clinical drug development of medicines in the pediatric population. 2 In 2012, the US Food and Drug Administration filed the Safety and Innovation Act, renewing and strengthening the Best Pharmaceuticals for Children Act, the Pediatric Research Equity Act and the Pediatric Medical Device Safety and Improvement Act. 3 The Pediatric Research Equity Act was amended by the Safety and Innovation Act to introduce the mandatory submission of a Pediatric Study Plan (PSP), typically at the end of clinical phase II.
In the quality part of both PIPs and pediatric study plan, the rational choice of the drug dosage form and its composition plays a major role. However, there is only one official regulatory document, the "Guideline on Pharmaceutical Development of Medicines for Paediatric Use" so far, released by the EMA. 4 For the first time ever, compulsory criteria for child-appropriate drug formulations are defined by this guideline.
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In general, child-appropriate drug formulations have the following key attributes 5 :
-Sufficient and predictable bioavailability and efficacy of the active pharmaceutical ingredient -Toxicologic safety of all components (including the excipients) -Correct and precise drug dosing (acceptable dose uniformity) -Acceptable properties (palatability, handling, etc) -Sociocultural acceptability (missing stigmatization) -Precise information on safe handling and administration of the medicine -"Child-proven" packaging
The impact of the key attributes may vary depending on the different maturation levels, life conditions, diseases, and individual preferences of children. In most cases, the child's age will be considered for categorization and dose selection. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use defines in its guideline on "Clinical Investigation of Medicinal Products in the Paediatric Population" 6 infants and toddlers (1-23 months), children (2-11 years), and adolescents (12-16 or 18 years). In the recent draft revision, the EMA states, however, "Chronologic age alone may not serve as an adequate categorical determinant to define developmental subgroups in pediatric studies. Physiological development and maturity of organs, pathophysiology of disease or condition, and the pharmacology of the investigational product are factors to be considered in determining the subgroups in pediatric studies." 7 In the EMA's "Reflection Paper: Formulations of Choice for the Paediatric Population" 8 the age category "children" (2-11 years) was further split into preschool (2-5 years) and school (6-11 years) children to introduce an age-related threshold for the swallowability of oral solid dosage forms. Recent clinical trials on the swallowability, acceptability, and preferences of children when receiving oral medicines question the evidence of this threshold (see section 5 of the Reflection Paper) formerly introduced by an expert group at the EMA. It is common understanding and also reflected in the EMA's guideline 4 that the suitability of solid dose carriers should be justified in relation to a child's age and maturation, health conditions, disease development and all risks associated with chewing on them, choking, aspiration, and over-or underdosing. Some attributes of a new pediatric drug formulation are the same as for a product for the adult population, but many are significantly different (see Table 1 ). New solid dosage forms with improved key attributes such as mini-tablets (defined as tablets with both diameter and height smaller than 3 mm), dispersible or orodispersible tablets, and orodispersible films broadened the opportunities for pediatric drug development by far and shifted the previous limits significantly. [9] [10] [11] These modern drug formulations are often considered as the dosage forms of choice.
11 Some authors claim a required shift of paradigm from the previously favored liquid formulations to the novel flexible solid dosage forms. 12 However, solid dosage forms might not serve for drug administration to neonates, which are a special subpopulation in this context. 13 Specific drug formulations for parenteral drug delivery of child-appropriate volumes and concentrations in the hospital setting, for example, with morphine or aminoglycosides, may be advantageous. In the next sections, we reflect the physiologic and pharmacokinetic basics, the choice of excipients, the impact of taste and texture sensation, the acceptability of medicines, the handling procedure and ease of drug administration on child-appropriate drug formulations, and finally, some thoughts on future perspectives of pediatric drug development. As the preferred and predominant route of administration is the oral route, the next sections will focus on the oral route of administration.
Administration Pathways
In general, the same routes of administration can be used in children as are common practice in adults. However, the developmental, physiologic, and pharmacokinetic differences of children may limit the opportunities. 13 While parenteral drug administration is common in pediatric wards, in particular in intensive care units, peroral drug administration is the most important modality to give medicines to children under domestic conditions. One of the most interesting and innovative therapeutic areas concerns cardiovascular drugs for children. Pharmaceutical companies had submitted 55 PIPs in the area of cardiovascular drugs by the end of January 2017.
14 Of these PIPs, 81.8% are dosage forms intended for oral use, whereas only 18.2% use the parenteral route of administration.
14 Further routes of administration for the pediatric population are rectal, cutaneous, nasal, conjunctival application, and inhalation. Because of the high variation of the skin permeation in pediatrics, almost no transdermal application route is used, in contrast to the adult population. Only occasionally, a systemic application of active pharmaceutical ingredients (APIs) is administered by inhalation or the transdermal or vaginal route.
Dosage Forms
The impact of administration routes and drug dosage forms has significantly changed in the pediatric population in the past years.
In the reflection paper "Formulations of Choice for the Paediatric Population," 8 the EMA described the state of pediatric dosage forms in 2005 and evaluated various application routes and dosage forms concerning their applicability for children. The EMA underlined that more dosage forms are necessary to cover the needs of all age groups. Based on expert opinions, without clinical evidence, recommendations were given regarding which dosage forms are preferable for different age classes and whether acceptance could be expected for the dosage forms. This has been criticized before. 15 According to the experts, solid dosage forms are acceptable only from preschool age on. New, important achievements in the past years were the development of solid dosage forms that enable flexible, precise, and low dosing for the pediatric population. Mini-tablets ( Figure 1 ) and orodispersible films ( Figure 2 ) containing age-appropriate dose strength enable easy application. [16] [17] [18] Mini-tablets typically have a diameter of 2 or 3 mm and include conventional mini-tablets (coated or uncoated) and orodispersible mini-tablets. Orodispersible mini-tablets provide the advantage of a very rapid integration directly in the mouth, which is a huge advantage for patients with swallowing difficulties. 16, 17 Examples of commercially available mini-tablets are Orfiril long (containing valproic acid; Bayer Vital GmbH Geschäftsbereich Pharma, Leverkusen, Germany) or Enzym Lefax forte (containing pancreatin; Bayer Vital GmbH Geschäftsbereich Pharma). Another dosage form providing an orodispersible character is the orodispersible film, which consists of a thin water-soluble polymer layer that integrates rapidly inside the mouth. In the past 2 years, several orodispersible film preparations have gained marketing authorization, for example, Setofilm R (Norgine B.V., Amsterdam, Netherlands) containing ondansetron indicated for the treatment of nausea and vomiting induced by cytotoxic chemotherapy 19 or Risperidon RHexal Schmelzfilm (Hexal Pharma GmbH, Vienna, Austria) indicated for the treatment of schizophrenia and mania. Orodispersible dosage forms offer an interesting alternative for children to conventional dosage forms. In 2008, the World Health Organization approved the benefits of solid dosage forms compared to liquid formulations and recommended the use of solid formulations also for infants and toddlers, 20 which could be explained by the higher stability of the dosage forms and the resulting lower distribution costs and higher global availability. Three years later, the EMA introduced the first draft of the "Guideline on Pharmaceutical Development of Medicines for Paediatric Use." 21 In this draft, in contrast to the solid formulations, liquid dosage forms, especially syrups, are described as acceptable from the day of birth. Therefore, no tablets with a diameter of 3 mm should be administered to children younger than 2 years old and no tablets with a diameter of 5 mm or higher should be given to children younger than 6 years old. Because of several complaints and objections concerning these age guidelines, the EMA published a new revised draft in 2013, in which no specific age recommendations for the acceptability of solid dosage forms were listed. Instead, it stated that acceptability of the dosage form should be justified and supported in any case by clinical evidence. 22 In 2014, the final version became effective, 4 which describes essential aspects for the formulation development of child-appropriate dosage forms, for example, the evaluation of the toxicity of excipients, the taste-sensing and taste evaluation, and the acceptability of dosage forms. The shift from liquid to solid formulations could also be confirmed by analyzing the PIPs in the cardiovascular field: In addition to the conventional solid dosage forms as capsules and tablets, there are also enteric coated mini-tablets, orodispersible minitablets, and an orodispersible film. 13 The solid formulations (70%) clearly predominate the liquid formulations (19%).
Pharmaceutical Excipients
The toxicology and compatibility of an API is mostly evaluated during comprehensive preclinical model investigations in line with the development of the medicinal product and proved with clinical studies in children of different age groups. For children, not only the toxicity of the API is of high importance, but also the clinical safety of the excipients, which has not been investigated systematically, neither in the past nor probably in the future. 23 Substances that were considered safe in higher amounts for the adult population, such as benzyl alcohol and propylene glycol, led to severe side effects in children, which in some cases were responsible for the death of the child. These substances cannot be metabolized by small children because the essential enzyme systems are not formed sufficiently at that point. These substances and resulting degradation products permeate the blood-brain barrier, which causes acute neurologic disorders, for example, in the worst case, seizures resulting in the death of the child. The current EMA guideline 4 offers a decision tree (Figure 3 ) that can be used during formulation development. According to the guideline, suitable documents of regulatory authorities of different sectors (eg, the food industry) or expert opinions with varying evidence levels can be consulted for the evaluation of excipients.
Approved documents of the Committee for Medicinal Products for Human Use of the EMA with high relevance are not available except for a new guideline on the use of phthalates and a consultation paper on the use of parabens despite the fact that parabens are known to be potentially harmful. 24 Furthermore, the European Study of Neonatal Exposure to Excipients has collected data for neonates regarding the safety, efficacy, and quality of excipients. 25 The European Paediatric Formulation Initiative is continuously working on the STEP (Safety and Toxicity of Excipients for Paediatrics) database, which provides toxicologic information on selected pharmaceutical excipients for pediatric use. 26 These methods should increase the safety for children but also enable the use of novel excipients and dosage forms for the pediatric population.
Taste Sensation and Taste Masking
If a medicinal product is refused by the patient because of its unpleasant taste, a therapeutic effect cannot be achieved. Human taste is generated by the binding of chemical compounds to taste receptors on the tongue. Five basic tastes can be distinguished: sweet, sour, bitter, umami, and salty. The human taste sensation is experienced quite subjectively, and children are more sensitive to bitter substances than adults. Therefore, the taste of the medicine is of crucial importance, and clinical trials with products that are sensed as unpleasant tasting within the pediatric population are pointless because the compliance of the patient at the time of dose administration mainly determines the bioavailability of the API. Medicinal products that are administered via the oral route should not generate an unpleasant taste. However, an enjoyable taste may increase the risk of intoxication in children. In general, a "neutral" taste is considered the most desirable taste sensation. Old and new methods for masking the bad taste enable the production of medicinal products that are adapted to children's taste, which can significantly differ from adult preferences. 27 Solid dosage forms can be coated with a saliva-resistant film that prevents disintegration inside the mouth and therefore leads to suppression of the bad taste. Matrices built out of fats or waxes can reduce the diffusion of the API, which leads to lower concentrations inside the saliva, and the taste-sensing receptors in the taste buds on the tongue cannot detect the API. Complexing agents like cyclodextrins or ion exchangers can be utilized in solid or liquid dosage forms. Here, the toxicology of these excipients plays an important role for the target patient population (see section 4 of the EMA's Reflection Paper). Reliable safety threshold values for neonates, for example, do not exist and are almost impossible to determine. Another major issue is the measuring or quantitation of a taste signal in early drug development, when API toxicity is still unknown. Taste trials with juvenile, healthy patients are prohibited in contrast to adults. However, an indicative knowledge should be present at the time of submitting a pediatric study plan or PIP. To overcome these problems, several attempts have been described in literature. The use of electronic tongues as a tool for investigations concerning taste-masking effects of excipients may give a hints whether the developed formulation will be accepted by the patients. 28 It could be shown that the electronic tongue measurements show a good correlation with in vivo taste-sensing studies. 29 Another nonhuman taste assessment model is the rat brief access taste aversion model, where the taste of substances is evaluated according the number of licks at the investigated substances by the rats. 30 Investigations showed that the brief access taste aversion model also revealed good correlation with human taste panels 31 and also with the results of electronic tongue measurements. 32 These nonhuman taste-sensing models are a promising tool for taste assessment during early drug development.
Acceptability of Drug Dosage Forms
In the relevant guideline, 4 the EMA provides a general definition of acceptability: "The overall ability and willingness of the patient to use and its care giver to administer the medicine as intended." Successful acceptability is demonstrated by the child's swallowing the medication reliably. Furthermore, the EMA lists factors that influence acceptability and demands clinical trials testing the acceptability of different dosage forms in children. How to adduce evidence for such acceptability is shown below using the example of minitablets with a diameter of 2 mm, which were administered to children in our children's university hospital. We focused our standardized assessment methodology on measuring acceptability including swallowability as defined and standardized in our studies [33] [34] [35] because they have proven to be reliable parameters to objectively assess the suitability of oral formulations for children, resulting in recommendations for the most appropriate oral pediatric formulations. Based on the results of a pilot study 33 with 60 children in 6 age groups aged from 6 months to 6 years, a confirmatory crossover study 34 was conducted in 306 children in the same age groups with placebo coated and uncoated minitablets in comparison to diluted 15% glucose syrup. The primary end point of this study was to investigate the acceptability of the uncoated mini-tablet. Sufficient acceptability was defined as immediate and complete swallowing of the administered dose (criterion 1) or swallowing of the main bolus after previous chewing (criterion 2). A significant superiority of the uncoated mini-tablet over the syrup over all age groups could be demonstrated. Even the acceptability of the coated mini-tablet was significantly superior to the syrup over all age groups (Figure 4) . The swallowability of the uncoated or coated mini-tablets was significantly superior to the syrup over all age groups. No significant difference between swallowability and acceptability of the coated and uncoated mini-tablet could be demonstrated. All 3 dosage forms were well tolerated. No child choked on the syrup or the uncoated mini-tablet. Only 2 of the 306 children (both in the age group of children aged 6 to 12 months) coughed after the administration of the coated mini-tablet, but in both cases without clinical relevance.
Because of the surprising acceptability of the minitablets in the age group of 6-to 12-month-old children, the question occurred whether solid dosage forms could be appropriate even for neonates. Therefore, a third clinical trial was performed in 151 neonates between 2 and 28 days old, 35 also taking into account late preterm neonates. Each child received in a randomized order one uncoated mini-tablet ( Figure 5 ) or 15% glucose syrup. In this study, the primary end point acceptability was a combination of the criteria "completely swallowed" and "partially swallowed." This acceptability was 100% for both the uncoated mini-tablet and the syrup (Figure 4) . Full swallowability as a secondary end point was higher for the mini-tablet (82.2%) than for the syrup (72.2%). No neonate choked on the mini-tablets or the syrup.
Because 1 mini-tablet often does not contain enough APIs, a forth clinical trial was performed to investigate the acceptability and swallowability of several hundred mini-tablets per application compared to syrup. A total of 374 children aged 6 months to 6 years were recruited and divided into 2 age groups (age group 1: 6-23 months; age group 2: 2-6 years). Age group 1 received 25 mini-tablets, 100 mini-tablets, and 5 mL of syrup. Age group 2 received 100 mini-tablets, 400 mini-tablets, and 10 mL of syrup. Superiority was demonstrated in age group 1 for acceptability and swallowability (both 25 and 100 mini-tablets) compared to syrup. In age group 2, noninferiority of acceptability was found only for 400 mini-tablets but not for 100 mini-tablets. Subgroup analysis revealed a strong sequential effect: if only comparing mini-tablets when given as a first dose, superiority was found for both doses compared to syrup. Noninferiority could be demonstrated for swallowability of 100 mini-tablets but not of 400 mini-tablets as compared to syrup. In the subgroup analysis, noninferiority was demonstrated when the children received 100 mini-tablets as a first dose but not when receiving them as a subsequent dose. The results of this clinical trial are currently awaiting publication.
Other working groups have also investigated the suitability of mini-tablets in the past few years. [36] [37] [38] [39] Thomson et al 40 were the first group to publish the findings of administration of 1 placebo uncoated minitablet (3-mm diameter) to children aged 2 to 6 years. The authors concluded that it was safe to use 3-mm mini-tablets in children aged 4 to 6 years because of their finding that only 46% of the 2-year-old children were able to swallow the mini-tablets, whereas up to 86% of the oldest children were capable of swallowing. However, the authors did not use a liquid control and did not include children younger than 2 years of age.
Van de Vijver et al 41 conducted a randomized phase II study in 16 children, aged 6 to 30 months, suffering from cystic fibrosis, in which 4 different doses of pancrelipase via 1 to 4 enteric coated, 2-mm-diameter minitablets were administered over 5 days. The primary end point of this study was the clinical efficacy of pancrelipase. Palatability of the mini-tablets was a secondary parameter, which was "scored fair to good by the parents in each of the treatment groups." 41 Van Riet-Nales et al. 37 investigated the acceptability of and the preference among different oral placebo formulations (4-mm tablets, syrup, suspension, and powder) in 148 infants and preschool children aged 1 to 4 years. The parents were asked to indicate the child's acceptability and the preference of the child and of themselves. Results showed that the tablets were the best-accepted formulation and that the tablets and the syrup were most preferred.
Kluk et al 38 performed a clinical trial in sixty 2-to 3-year-old children testing the acceptability of several mini-tablets administered at one time, which showed that most of the children were able to swallow 5 to ten 2-and 3-mm mini-tablets with soft food.
In the pharmaceutical industry, those systematically designed and conducted acceptability studies led to a tremendous change. Various companies switched from the early development of liquid formulations such as syrups, drops, or juices to the development of multiparticulates such as mini-tablets or pellets. This could be reflected in the current PIPs, for example, in the area of cardiovascular diseases. Mini-tablets can be produced on conventional tableting machines, at least if the APIs and the appropriate excipients can be easily compressed to a tablet, do not need risky excipients, and often show a higher stability in comparison with the liquid formulations. If the minitablet is also orodispersible and disintegrates within the oral cavity, an ideal child-appropriate dosage form may be accomplished. 16 Orodispersible mini-tablets stay stable within the primary package, are easy to handle, and after administration behave nearly like a liquid formulation but without their risky excipients such as preservatives, antioxidants, or organic solvents. They enable a precise dose adjustment and a specific dose titration of the API. Since 2015, the first orodispersible mini-tablets containing 0.25 mg and 1.0 mg of enalapril maleate have been utilized within a multicenter clinical trial for the treatment of congenital heart failure in children of all age groups, from birth to adolescence.
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Handling and Administration
Child-appropriate dosage forms often also must be parent-friendly for administration at home because parents prepare the medicinal product for administration and give it to their children. Commercial dry syrups often are difficult to prepare and afterward to apply the correct dose-for parents as well as for experts. 42 Clear instructions in the information texts such as the package insert or professional information are of high importance.
Application devices ensure the better, easier, or safer administration of dosage forms. Also, discrete administration can be beneficial to protect children from blame and mockery. Medical devices, especially within the pediatric area, are of high importance because administration of the drug is often quite challenging. 43 Modern medical devices for liquid medicinal preparations show a distinct trend to oral syringes. Beside exact dosing and easy application, complete draining and easy cleaning are some of the advantages over commercial measuring caps or spoons. 32 New, innovative application systems were introduced recently to ensure precise dosing by administering multiple pellets or mini-tablets. 44 Now, various systems that work mechanically or with electronics are available. Some systems even enable connection to a smartphone to increase patient compliance. 45 Other innovative administration devices for solids were introduced to the market recently. To combine a precise application of multiparticulate dosage forms and easy handling with potential taste masking, a straw has been developed that enables the application of pellets in various beverages ( Figure 6A) . 46 In addition, a device for highprecision dosing of liquid formulations was developed ( Figure 6B ). These efforts show that much research focuses on the development of precise application tools for the pediatric population to improve the compliance and safety of the treatment.
Future Perspectives for Pediatric Drug Formulations
Many medicines for children are presently under development, which will lead to important innovations for the future and bridge existing gaps in the supply of appropriate medicinal products for the pediatric population. Because of the complex clinical studies and the elaborate approval process, it will take time, but the European legislature has already changed a great deal concerning pediatric medicine. The most recent 10-year report of the EMA to the European Commission 47 illustrates an increase in clinical studies conducted in the pediatric population, a tremendous number of submitted and reviewed PIPs, but only a few Paediatric Use Marketing Authorisations for off-patent drug substances. Obviously, the benefits of a 10-year exclusivity period for the generated clinical data have been overestimated by the authors of the European pediatric guideline. Another reason for this disappointing outcome of the Paediatric Use Marketing Authorisation incentive could be reimbursement issues in the various member states, which reduce the profit margins of the pharmaceutical sponsors. Extraordinary high prices are often not accepted by the insurance companies or the hospital pharmacies, which may prefer to extemporaneously compound the medicines as they did before the marketing authorization. 48 Therefore, high-quality magistral preparations for hospital and community pharmacies (where it is still feasible) will be required today and in the future. The Council of Europe, in which there are many more member states than in the European Union, has filed a resolution for the preparation of medicinal products in pharmacies 49 in order to standardize and to improve quality and to ensure the safety of extemporaneous preparations. 50 At the European Directorate for the Quality of Medicines, a working group has been established to generate a pediatric formulary based on predefined specifications with recipes of high-standard and well-established preparations. It should not replace existing or upcoming market authorizations of medicinal products, but bridge the existing gaps in pediatric drug treatment.
Potentially, new dosage forms will show up for extemporaneous compounding like orodispersible films 18 and novel manufacturing technologies such as drug printing could offer more opportunities. 51 
Conclusions
This article focuses on recent developments in the field of pediatric oral dosage forms, the most frequent and convenient mode of administration of medicine to children. New solid dosage forms have recently reached clinical practice. Mini-tablets have proven to be a safe, reliable, and easy dose approach to administer oral medication to young children. The basis for a broad use of this new pharmaceutical dosage form for many different drug classes and treatment options in the near future was provided. Various successful trials on the acceptability and swallowability of mini-tablets have demonstrated that this dosage form might be a suitable platform for the pharmaceutical industry. But there are still many more investigations required. Orodispersible formulations that could be based on films, tablets, and mini-tablets show evidence for being acceptable replacements for the classical liquid formulations in the future.
Due to the comprehensive authorization process and lacking financial incentives, there will still be a need for off-patent drug substances in the future. Activities to standardize compendial extemporaneous preparations are appreciated in order to ensure the efficacy and safety of compounded medicines. Overall, the various political incentives in both the European Union and the United States seem to bring a change in pediatic drug formulations and will improve the present situation by far.
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